These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38470964)

  • 21. Disappearance of lentigines in a patient receiving imatinib treatment for familial gastrointestinal stromal tumor syndrome.
    Campbell T; Felsten L; Moore J
    Arch Dermatol; 2009 Nov; 145(11):1313-6. PubMed ID: 19917964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. C-kit, GIST, and imatinib.
    Siehl J; Thiel E
    Recent Results Cancer Res; 2007; 176():145-51. PubMed ID: 17607922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042.
    Koon HB; Krown SE; Lee JY; Honda K; Rapisuwon S; Wang Z; Aboulafia D; Reid EG; Rudek MA; Dezube BJ; Noy A
    J Clin Oncol; 2014 Feb; 32(5):402-8. PubMed ID: 24378417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperpigmentation due to imatinib: A rare case of cutaneous involvement.
    Rehman H; Hakim N; Sugarman R; Seetharamu N; Saif MW
    J Oncol Pharm Pract; 2020 Sep; 26(6):1511-1515. PubMed ID: 32067560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dermatological toxicity of imatinib mesylate.
    Prasad N; Deshmukh C; Biswas G; Bakshi A; Sastry PS; Parikh PM
    J Assoc Physicians India; 2005 Apr; 53():298. PubMed ID: 15987015
    [No Abstract]   [Full Text] [Related]  

  • 26. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
    Hong JL; Li J; Li J; Shen L
    Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of c-kit receptor in human cholangiocarcinoma and in vivo treatment with imatinib mesilate in chimeric mice.
    Kamenz T; Caca K; Blüthner T; Tannapfel A; Mössner J; Wiedmann M
    World J Gastroenterol; 2006 Mar; 12(10):1583-90. PubMed ID: 16570351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular response to imatinib in KIT F522C-mutated systemic mastocytosis.
    Broderick V; Waghorn K; Langabeer SE; Jeffers M; Cross NCP; Hayden PJ
    Leuk Res; 2019 Feb; 77():28-29. PubMed ID: 30612056
    [No Abstract]   [Full Text] [Related]  

  • 29. Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review.
    Oliveira SR; de Azevedo Branco LG; Rocha AL; Travassos DV; Magalhães GHR; Fonseca FP; Mesquita RA; Abreu LG; da Silva TA
    Clin Oral Investig; 2019 Dec; 23(12):4371-4382. PubMed ID: 30968242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.
    Verboom MC; Kloth JSL; Swen JJ; van der Straaten T; Bovée JVMG; Sleijfer S; Reyners AKL; Mathijssen RHJ; Guchelaar HJ; Steeghs N; Gelderblom H
    Eur J Cancer; 2017 Nov; 86():226-232. PubMed ID: 29054076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Re: Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis.
    Tamborini E; Negri T; Miselli F; Lagonigro MS; Pricl S; Pilotti S
    J Natl Cancer Inst; 2006 Nov; 98(21):1583-4. PubMed ID: 17077361
    [No Abstract]   [Full Text] [Related]  

  • 32. Successful treatment with imatinib after nilotinib and ipilimumab in a c-kit-mutated advanced melanoma patient: a case report.
    Murer C; Kränzlin-Stieger P; French LE; Dummer R; Goldinger SM
    Melanoma Res; 2017 Aug; 27(4):396-398. PubMed ID: 28410286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [KIT and KIT: from biology to clinical use].
    Curtit E; Mansi L; Viel E; Dobi E; Chaigneau L; Nguyen T; Pivot X; Blay JY; Kalbacher E
    Bull Cancer; 2012 Feb; 99(2):191-7. PubMed ID: 21669561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secondary resistance to imatinib mesylate in a patient with unresectable duodenal GIST without mutations in exons 9, 11, 13, or 17 of the c-kit protooncogene.
    Yamaguchi M; Matsumoto T; Tate G; Higuchi T
    J Gastroenterol; 2004 Sep; 39(9):904-5. PubMed ID: 15565413
    [No Abstract]   [Full Text] [Related]  

  • 35. Molecular research directions in the management of gastrointestinal stromal tumors.
    Tarn C; Godwin AK
    Curr Treat Options Oncol; 2005 Nov; 6(6):473-86. PubMed ID: 16242052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ex vivo evaluation of imatinib mesylate for induction of cell death on canine neoplastic mast cells with mutations in c-Kit exon 11 via apoptosis.
    Rossi G; Bertani C; Mari S; Marini C; Renzoni G; Ogilvie G; Magi GE
    Vet Res Commun; 2013 Jun; 37(2):101-8. PubMed ID: 23315207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Flashback Foreword: Kinase Mutations and Imatinib Response in Patients With Metastatic GI Stromal Tumor.
    Maki RG
    J Clin Oncol; 2023 Nov; 41(31):4827-4828. PubMed ID: 37890276
    [No Abstract]   [Full Text] [Related]  

  • 38. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations.
    Cristofanilli M; Morandi P; Krishnamurthy S; Reuben JM; Lee BN; Francis D; Booser DJ; Green MC; Arun BK; Pusztai L; Lopez A; Islam R; Valero V; Hortobagyi GN
    Ann Oncol; 2008 Oct; 19(10):1713-9. PubMed ID: 18515258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
    Guo J; Si L; Kong Y; Flaherty KT; Xu X; Zhu Y; Corless CL; Li L; Li H; Sheng X; Cui C; Chi Z; Li S; Han M; Mao L; Lin X; Du N; Zhang X; Li J; Wang B; Qin S
    J Clin Oncol; 2011 Jul; 29(21):2904-9. PubMed ID: 21690468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Systemic mastocytosis without the typical mutation of codon 816 successfully treated with imatinib].
    Hirayama Y; Konuma Y; Kohda K; Ando M; Obata M; Ueno Y; Sasagawa Y; Wada Y; Shirao S
    Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2542-5. PubMed ID: 19051746
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.